Skip to main content

Table 1 Baseline and endpoint assessments in completers in the TACIT and CARDERA trials (mean scores (95 % confidence intervals))

From: Optimal responses in disease activity scores to treatment in rheumatoid arthritis: Is a DAS28 reduction of >1.2 sufficient?

EULAR Response Number DAS28 HAQ EQ5D
   Initial Endpoint Initial Endpoint Initial Endpoint
CARDERA trial
None 121 5.45 (5.22, 5.68) 5.67 (5.45, 5.89) 1.43 (1.30, 1.56 1.53 (1.39, 1.67) 0.46 (0.40, 0.51) 0.48 (0.43, 0.53)
Moderate 160 6.08 (5.89, 6.27) 4.21 (4.07, 4.35) 1.70 (1.60, 1.80) 1.31 (1.20, 1.42) 0.42 (0.37, 0.46) 0.60 (0.56, 0.63)
Good 98 5.57 (5.33, 5.80) 2.17 (2.04, 2.30) 1.47 (1.35, 1.60) 0.60 (0.48, 0.72) 0.47 (0.42, 0.52) 0.77 (0.73, 0.80)
TACIT trial
None 34 6.40 (6.08, 6.71) 6.34 (6.06, 6.63) 2.15 (2.00, 2.29) 2.11 (1.94, 2.28) 0.22 (0.11, 0.33) 0.23 (0.13, 0.34)
Moderate 86 6.30 (6.11, 6.49) 4.23 (4.07, 4.38) 1.91 (1.78, 2.04) 1.58 (1.42, 1.73) 0.41 (0.35, 0.47) 0.56 (0.51, 0.61)
Good 66 6.13 (5.96, 6.30) 2.29 (2.14, 2.44) 1.64 (1.47, 1.81) 1.00 (0.81, 1.19) 0.40 (0.32, 0.47) 0.69 (0.64, 0.75)
  1. TACIT tumour necrosis factor inhibitors against combination intensive therapy, CARDERA cost-effectiveness of treatment strategies using combination of disease modifying anti-rheumatic drugs and glucocorticoids in early rheumatoid arthritis, EULAR European League Against Rheumatism, DAS28 twenty-eight joint disease activity score, HAQ Health Assessment Questionnaire, EQ5D Euroqol-5D